Status:

COMPLETED

Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Lead Sponsor:

Imperial College London

Collaborating Sponsors:

Millennium Pharmaceuticals, Inc.

Conditions:

Lung Diseases, Obstructive

Eligibility:

All Genders

40-80 years

Phase:

PHASE1

Brief Summary

This is a clinical research study to assess whether after exhaling a single cigarette smoke through the nose there are changes in the inflammatory cells and proteins of nasal secretions. A single blo...

Detailed Description

Introduction Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that causes widespread morbidity and mortality, the Global Burden of Disease Study estimating COPD to be curre...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (COPD Smokers):
  • Smokers currently on at least 5 cigarettes per day, with a history of \>10 pack years
  • Post-bronchodilator FEV1 \>30% of predicted and \< 80% of predicted
  • Pre-bronchodilator FEV1/FVC of \<70%
  • With or without chronic simple bronchitis
  • Exclusion criteria (COPD Smokers):
  • History of asthma, allergy (including rhinitis/eczema)
  • Reversibility : an increase in FEV1 that is \>400ml from the baseline pre- bronchodilator value (bronchodilate with salbutamol 400g delivered from a metered dose inhaler (MDI) into a spacer).
  • Inclusion criteria (for "Healthy" Smokers):
  • Smokers currently on at least 5 cigarettes per day, with a history of \>10 pack years
  • FEV1 \>90% of predicted, FEV1/FVC of \>70%
  • Cannot have chronic simple bronchitis
  • Age, sex, smoking history matched to COPD Smokers
  • Exclusion criteria (for "Healthy" Smokers):
  • History of asthma, allergy (including rhinitis/eczema
  • Reversibility: an increase in FEV1 that is both \>400ml from the baseline pre-bronchodilator value (bronchodilate with salbutamol 400mcg delivered from a metered dose inhaler (MDI) into a spacer)P
  • Pregnancy

Exclusion

    Key Trial Info

    Start Date :

    September 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2006

    Estimated Enrollment :

    16 Patients enrolled

    Trial Details

    Trial ID

    NCT00159341

    Start Date

    September 1 2005

    End Date

    December 1 2006

    Last Update

    September 14 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Heart & Lung Institue Clinical Studies Unit, Imperial College London

    London, United Kingdom, SW3 6HP